Clinical trialPhase 4Withdrawn
Pasireotide Treatment for Neuroendocrine Tumor
Pasireotide Treatment for Insulin Producing Pancreatic Neuro-endocrine Tumor
- Outcome
- Stopped earlySubject passed away prior to enrollment (Enrollment)
- Phase
- Phase 4
- Status
- Withdrawn
- Study type
- Interventional
- Planned start
- April 2016
- Planned end
- June 2016
- Enrollment
- 0 participants
- Sites
- 0
- Primary outcomes
- Hypoglycemia
- Sponsor type
- Academic / other
- Results posted
- No
- Last update
- 4 March 2022
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
Pasireotide binds to somatostatin receptors sst2 and sst5, which can lead to significant hyperglycemia. The investigators would like to administer pasireotide as a treatment for refractory hypoglycemia in the setting of metastatic insulin-producing pancreatic neuro-endocrine tumor.